×
About 30,208 results

ALLMedicine Amyotrophic Lateral Sclerosis Center

Research & Reviews  14,539 results

Synaptic restoration by cAMP/PKA drives activity-dependent neuroprotection to motoneuro...
https://doi.org/10.1084/jem.20191734
The Journal of Experimental Medicine; Bączyk M, Alami NO et. al.

Jun 2nd, 2020 - Excessive excitation is hypothesized to cause motoneuron (MN) degeneration in amyotrophic lateral sclerosis (ALS), but actual proof of hyperexcitation in vivo is missing, and trials based on this concept have failed. We demonstrate, by in vivo sin...

The involvement of regulatory T cells in amyotrophic lateral sclerosis and their therap...
https://doi.org/10.1080/21678421.2020.1752246
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Giovannelli I, Heath P et. al.

Jun 2nd, 2020 - Neuroinflammation, meaning the establishment of a diffuse inflammatory condition in the CNS, is one of the main hallmarks of amyotrophic lateral sclerosis (ALS). Recently, a crucial role of regulatory T cells (Tregs) in this disease has been outli...

Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longi...
https://doi.org/10.1080/21678421.2020.1771732
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Bersano E, Sarnelli MF et. al.

Jun 2nd, 2020 - Background: A cognitive impairment, ranging from frontotemporal dementia (FTD) to milder forms of dysexecutive or behavioral dysfunction, is detected in 30-50% of patients affected by amyotrophic lateral sclerosis (ALS) at diagnosis. Such conditio...

C9orf72 suppresses systemic and neural inflammation induced by gut bacteria.
https://doi.org/10.1038/s41586-020-2288-7
Nature Burberry A, Wells MF et. al.

Jun 2nd, 2020 - A hexanucleotide-repeat expansion in C9ORF72 is the most common genetic variant that contributes to amyotrophic lateral sclerosis and frontotemporal dementia1,2. The C9ORF72 mutation acts through gain- and loss-of-function mechanisms to induce pat...

Tamoxifen for amyotrophic lateral sclerosis: A randomized double-blind clinical trial.
https://doi.org/10.1097/MD.0000000000020423
Medicine Chen PC, Hsieh YC et. al.

Jun 1st, 2020 - Amyotrophic lateral sclerosis (ALS) is the most common cause of motor neuron disease, and effective treatment for ALS is still lacking. Transactive response (TAR) -DNA-binding protein-43 (TDP-43) is aggregated in the neurons of ALS patients. Anima...

see more →

Guidelines  9 results

Aquestive Therapeutics Receives FDA Approval for Exservan (riluzole) Oral Film
http://aquestive.com/aquestive-therapeutics-receives-fda-approval-for-exservan-riluzole-oral-film/

Nov 24th, 2019 - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that Exservan™ (riluzole) Oral Film received early-act...

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 8th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

MDA U.S. Neuromuscular Disease Registry
https://www.mda.org/services/neuromuscular-disease-registry
Muscular Dystrophy Association (USA)

Dec 31st, 2015 - In 2013, MDA launched the U. S.

EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--rev...
https://doi.org/10.1111/j.1468-1331.2011.03501.x
European Journal of Neurology; , Andersen PM et. al.

Sep 14th, 2011 - The evidence base for the diagnosis and management of amyotrophic lateral sclerosis (ALS) is weak. To provide evidence-based or expert recommendations for the diagnosis and management of ALS based on a literature search and the consensus of an exp...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 13th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  27 results see all →

Clinicaltrials.gov  15,051 results

Synaptic restoration by cAMP/PKA drives activity-dependent neuroprotection to motoneuro...
https://doi.org/10.1084/jem.20191734
The Journal of Experimental Medicine; Bączyk M, Alami NO et. al.

Jun 2nd, 2020 - Excessive excitation is hypothesized to cause motoneuron (MN) degeneration in amyotrophic lateral sclerosis (ALS), but actual proof of hyperexcitation in vivo is missing, and trials based on this concept have failed. We demonstrate, by in vivo sin...

The involvement of regulatory T cells in amyotrophic lateral sclerosis and their therap...
https://doi.org/10.1080/21678421.2020.1752246
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Giovannelli I, Heath P et. al.

Jun 2nd, 2020 - Neuroinflammation, meaning the establishment of a diffuse inflammatory condition in the CNS, is one of the main hallmarks of amyotrophic lateral sclerosis (ALS). Recently, a crucial role of regulatory T cells (Tregs) in this disease has been outli...

Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longi...
https://doi.org/10.1080/21678421.2020.1771732
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Bersano E, Sarnelli MF et. al.

Jun 2nd, 2020 - Background: A cognitive impairment, ranging from frontotemporal dementia (FTD) to milder forms of dysexecutive or behavioral dysfunction, is detected in 30-50% of patients affected by amyotrophic lateral sclerosis (ALS) at diagnosis. Such conditio...

C9orf72 suppresses systemic and neural inflammation induced by gut bacteria.
https://doi.org/10.1038/s41586-020-2288-7
Nature Burberry A, Wells MF et. al.

Jun 2nd, 2020 - A hexanucleotide-repeat expansion in C9ORF72 is the most common genetic variant that contributes to amyotrophic lateral sclerosis and frontotemporal dementia1,2. The C9ORF72 mutation acts through gain- and loss-of-function mechanisms to induce pat...

Tamoxifen for amyotrophic lateral sclerosis: A randomized double-blind clinical trial.
https://doi.org/10.1097/MD.0000000000020423
Medicine Chen PC, Hsieh YC et. al.

Jun 1st, 2020 - Amyotrophic lateral sclerosis (ALS) is the most common cause of motor neuron disease, and effective treatment for ALS is still lacking. Transactive response (TAR) -DNA-binding protein-43 (TDP-43) is aggregated in the neurons of ALS patients. Anima...

see more →

News  555 results

'Clear Signature' of ALS Found in Children's Teeth
https://www.medscape.com/viewarticle/931022

May 21st, 2020 - Adults who develop amyotrophic lateral sclerosis (ALS) metabolize metals differently than those who do not develop the neurodegenerative disease, and this shows up in teeth during childhood, new research suggests. Investigators found increased upt...

Post Hoc Data Suggest Edaravone Helpful in Bulbar-Onset ALS
https://www.medscape.com/viewarticle/927761

Mar 30th, 2020 - NEW YORK (Reuters Health) - For patients with bulbar-onset amyotrophic lateral sclerosis (ALS), initiating treatment with edaravone appears to provide a benefit in terms of physical functioning regardless of baseline lung function, according to a ...

New Data Rank Neurologic Diagnoses by Suicide Risk
https://www.medscape.com/viewarticle/924775

Feb 3rd, 2020 - A small but significant increase in the risk for death by suicide occurs in the months immediately following diagnosis of specific neurologic disorders, results of a large, population-based study of more than 7 million individuals show. Patients d...

RimabotulinumtoxinB Reduces Sialorrhea in Adults
https://www.medscape.com/viewarticle/923790

Jan 15th, 2020 - NEW YORK (Reuters Health) - RimabotulinumtoxinB (RIMA) safely reduces sialorrhea in adults, according to results from the phase 3 MYSTICOL clinical trial. Sialorrhea, the excess spillage of saliva from the mouth, affects up to 74% of people with P...

New Disability Scale Better Assesses ALS Outcomes
https://www.medscape.com/viewarticle/923295

Jan 2nd, 2020 - NEW YORK (Reuters Health) - A new amyotrophic lateral sclerosis (ALS) disability scale (ROADS) that uses the mathematically rigorous Rasch methodology outperforms the revised ALS Functional Rating Scale (ALSFRS-R) in measuring ALS patient-reported...

see more →

Patient Education  27 results see all →